US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Neurizon Therapeutics Ltd (PAAOA) 銘柄情報

Neurizon Therapeutics Ltd (PAAOA)

0.11

0.00

(0.00%)

終了 6月29日 3:00PM

Neurizon Therapeutics Ltd (PAAOA) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.11

( - )

買値

0.11

売値

0.12

出来高

0.00

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

0.11

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 722,505

発行済株式数

746,274,115

配当利回り

PER

-1.97

1 株当たり利益 (EPS)

-0.03

歳入

5.98M

純利益

-14.85M

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II... Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.neurizon.com

本社

Melbourne, Australia

設立

2026

Neurizon Therapeutics Ltd is listed in the sector of the オーストラリア証券取引所 with ticker PAAOA. The last closing price for Neurizon Therapeutics was AUD0.11. Over the last year, Neurizon Therapeutics shares have traded in a share price range of AUD 0.00 to AUD 0.00.

Neurizon Therapeutics currently has 746,274,115 shares in issue. The market capitalisation of Neurizon Therapeutics is AUD82.09 million. Neurizon Therapeutics has a price to earnings ratio (PE ratio) of -1.97.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

PAAOA - Frequently Asked Questions (FAQ)

What is the current Neurizon Therapeutics Ltd share price?

The current share price of Neurizon Therapeutics Ltd is AUD 0.11

How many Neurizon Therapeutics Ltd shares are in issue?

Neurizon Therapeutics Ltd has 746,274,115 shares in issue

What is the market cap of Neurizon Therapeutics Ltd?

The market capitalisation of Neurizon Therapeutics Ltd is AUD 82.09M

What is the 1 year trading range for Neurizon Therapeutics Ltd share price?

Neurizon Therapeutics Ltd has traded in the range of AUD 0.00 to AUD 0.00 during the past year

What is the PE ratio of Neurizon Therapeutics Ltd?

The price to earnings ratio of Neurizon Therapeutics Ltd is -1.97

What is the cash to sales ratio of Neurizon Therapeutics Ltd?

The cash to sales ratio of Neurizon Therapeutics Ltd is 7.24

What is the registered address of Neurizon Therapeutics Ltd?

The registered address for Neurizon Therapeutics Ltd is Suite 2, Melbourne, Victoria, 3000

What is the Neurizon Therapeutics Ltd website address?

The website address for Neurizon Therapeutics Ltd is www.neurizon.com

US Market News

US Market News 3分前

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor AssessmentJune 29, 2026 3:00 AM
Business Wire IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment.

US Market News

US Market News 4分前

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental VitiligoJune 29, 2026 3:00 AM
PR Newswire (US) If approved, upadacitinib is expected to be the first systemi

US Market News

US Market News 4分前

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental VitiligoJune 29, 2026 3:00 AM
PR Newswire (US) If approved, upadacitinib is expected to be the first systemi

US Market News

US Market News 4分前

UK&I Clients Rank EPAM #1 for General Satisfaction in Whitelane Research ReportJune 29, 2026 3:02 AM
PR Newswire (US) Backed by strong client evaluations, EPAM's #1 rankings in general satisfaction, application services and service delive

US Market News

US Market News 4分前

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia AreataJune 29, 2026 3:10 AM
PR Newswire (US) Positive CHMP opinion is supported by data from the Phase 3 U

US Market News

US Market News 4分前

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia AreataJune 29, 2026 3:10 AM
PR Newswire (US) Positive CHMP opinion is supported by data from the Phase 3 U

threewheeler

threewheeler 20分前

https://x.com/KRTLICC/status/2071377547888382410

threewheeler

threewheeler 22分前

https://x.com/KRTLICC/status/2071377547888382410

threewheeler

threewheeler 23分前

https://x.com/KRTLICC/status/2071377547888382410

uber darthium

uber darthium 27分前

The gurly runt man, now former gurly man president of MAXD was nothing but a drug fueled fraudster that got sent back home to live with mommy and daddy after destroying each and every investor’s money

Greg Halpern is an outright fraud, in my opinion

I have a pretty goo

StockItOut

StockItOut 32分前

Which contract Xeriant claiming in breach?
The JV Agreement?
or some other,
like a letter? -An un-mutually signed Xeriant letter?

Are you talking about some supplemental extension of the JV Agreement contract where in kind we see nothing of agreement stated in wr

walterc

walterc 39分前

I feel that going in a conversation with you is a waste of time;
Investing in a company where you believe management are liars and incompetent and then writing about 12000 posts on that company is insane.
If you happen to come to the groundbreaking , please put a badge on with PUT

StockItOut

StockItOut 43分前

just commenting on your pumping garbage

chart wise / technical wise, your point is decent.

irony, it shows your DDAmanda product a fraud.

.

GreenOverGreed

GreenOverGreed 47分前

Lots of chatter this weekend, so I dropped another article:

https://x.com/GreenOverGreed1/status/2071462892982222897?s=20

knrorrel

knrorrel 1時間前

watch $ADTX now 🔥🔥🔥

knrorrel

knrorrel 1時間前

i think YEES , i add. some
imo

knrorrel

knrorrel 1時間前

barrymarshal00

barrymarshal00 1時間前

Fenbendazole 222 mg – Trusted Deworming Medicine in Australia for Intestinal Parasite Control

Fenbendazole 222 mg is an anthelmintic drug that is characterized by highly antiparasitic properties and efficiency in combating different kinds of infections caused by intestinal parasites.

knrorrel

knrorrel 1時間前

https://stockcharts.com/sc3/ui/?s=ADTX

knrorrel

knrorrel 1時間前

mega strong oversold

CA Market News

CA Market News 1時間前

Eco (Atlantic) Oil and Gas Ltd. Announces Ministerial Approval for Namibia PEL 98 Farm-OutJune 29, 2026 2:00 AM
ACCESS NewswirePEL97,99 & 100, and South Africa Block 1 Section 11 Processes UnderwayTORONTO, ON /

sam1933

sam1933 1時間前

HBAR TARGET EOY
chart « Entering the circle of trust » GO E7!
https://investorshub.advfn.com/uimage/uploads/2026/6/29/rgsqzHBAR-USD_2026-06-28_22-49-25.png

mgland

mgland 1時間前

silence
https://www.youtube.com/shorts/rBv6iZCdJ10

BudSparrow

BudSparrow 1時間前

Given 15 years of your record I would not cross the street if you told me it was clear. Just saying.
I've been reading RD's posts for five years, not because his predictions are accurate, but because he gives me hope. It's kind of like he reminds me every day that I have a big, fat lottery t

gdl

The Forever War has the market on edge. but like all things evil they get used to it and thrive after. So maybe tomorrow we THRIVE!
The Monthly SPX candlestick patterns are downright extremely BULLISH. I still see no change from that. I would be hard pressed to expect a deep drop here with t

Neurizon Therapeutics

BNP PARIBAS EASY II USD ...

Technical Publications S...

YouneeqAI Technical Serv... (EM)

NYLI Candriam US Large C...

Nuveen Select Maturities...

Neptune Digital Assets (QB)

WisdomTree US Total Market

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。